Skip to content
20-F

Annual Report (Foreign)

Calliditas Therapeutics AB

0001410578-24-000528

← back to feed
Filed
Apr 24, 2024 12:00 AM ET
Period of report
—

On SEC.gov

Filing index ↗

Financials in this filing

Metric Period Value
Shares Diluted FY 2023 · Dec 31, 2023 53.67M sh
Shares Diluted FY 2023 · Dec 31, 2022 53.02M sh
Shares Diluted FY 2023 · Dec 31, 2021 50.83M sh
Shares Outstanding FY 2023 · Dec 31, 2023 59.58M sh
Operating Cash Flow FY 2023 · Dec 31, 2023 −434.66M
Operating Cash Flow FY 2023 · Dec 31, 2022 −311.35M
Operating Cash Flow FY 2023 · Dec 31, 2021 −461.59M
Cash And Equivalents FY 2023 · Dec 31, 2023 973.73M
Cash And Equivalents FY 2023 · Dec 31, 2022 1.25B
Cash And Equivalents FY 2023 · Dec 31, 2021 955.51M
Current Liabilities FY 2023 · Dec 31, 2023 407.14M
Current Liabilities FY 2023 · Dec 31, 2022 325.23M
Current Assets FY 2023 · Dec 31, 2023 1.28B
Current Assets FY 2023 · Dec 31, 2022 1.41B
Total Assets FY 2023 · Dec 31, 2023 1.86B
Total Assets FY 2023 · Dec 31, 2022 1.95B
Eps Diluted FY 2023 · Dec 31, 2023 −8.69
Eps Diluted FY 2023 · Dec 31, 2022 −7.78
Eps Diluted FY 2023 · Dec 31, 2021 −9.84
Eps Basic FY 2023 · Dec 31, 2023 −8.69
Eps Basic FY 2023 · Dec 31, 2022 −7.78
Eps Basic FY 2023 · Dec 31, 2021 −9.84
Rd Expense FY 2023 · Dec 31, 2023 502.22M
Rd Expense FY 2023 · Dec 31, 2022 414.75M
Rd Expense FY 2023 · Dec 31, 2021 357.49M
Net Income FY 2023 · Dec 31, 2023 −466.19M
Net Income FY 2023 · Dec 31, 2022 −412.27M
Net Income FY 2023 · Dec 31, 2021 −509.54M
Operating Income FY 2023 · Dec 31, 2023 −373.06M
Operating Income FY 2023 · Dec 31, 2022 −421.94M
Operating Income FY 2023 · Dec 31, 2021 −524.46M
Gross Profit FY 2023 · Dec 31, 2023 1.15B
Gross Profit FY 2023 · Dec 31, 2022 787.68M
Gross Profit FY 2023 · Dec 31, 2021 229.35M
Cost Of Revenue FY 2023 · Dec 31, 2023 60.46M
Cost Of Revenue FY 2023 · Dec 31, 2022 15.2M